JP2022500419A5 - - Google Patents

Info

Publication number
JP2022500419A5
JP2022500419A5 JP2021513959A JP2021513959A JP2022500419A5 JP 2022500419 A5 JP2022500419 A5 JP 2022500419A5 JP 2021513959 A JP2021513959 A JP 2021513959A JP 2021513959 A JP2021513959 A JP 2021513959A JP 2022500419 A5 JP2022500419 A5 JP 2022500419A5
Authority
JP
Japan
Prior art keywords
domain
cytotoxic
receptor
population
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513959A
Other languages
English (en)
Japanese (ja)
Other versions
JP7520818B2 (ja
JP2022500419A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/050679 external-priority patent/WO2020056045A1/en
Publication of JP2022500419A publication Critical patent/JP2022500419A/ja
Publication of JP2022500419A5 publication Critical patent/JP2022500419A5/ja
Priority to JP2024110682A priority Critical patent/JP2024149496A/ja
Application granted granted Critical
Publication of JP7520818B2 publication Critical patent/JP7520818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513959A 2018-09-13 2019-09-11 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 Active JP7520818B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024110682A JP2024149496A (ja) 2018-09-13 2024-07-10 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862730939P 2018-09-13 2018-09-13
US62/730,939 2018-09-13
US201962821360P 2019-03-20 2019-03-20
US62/821,360 2019-03-20
US201962841768P 2019-05-01 2019-05-01
US62/841,768 2019-05-01
US201962875893P 2019-07-18 2019-07-18
US62/875,893 2019-07-18
PCT/US2019/050679 WO2020056045A1 (en) 2018-09-13 2019-09-11 Natural killer cell compositions and immunotherapy methods for treating tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024110682A Division JP2024149496A (ja) 2018-09-13 2024-07-10 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法

Publications (3)

Publication Number Publication Date
JP2022500419A JP2022500419A (ja) 2022-01-04
JP2022500419A5 true JP2022500419A5 (enExample) 2022-09-20
JP7520818B2 JP7520818B2 (ja) 2024-07-23

Family

ID=69778429

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513959A Active JP7520818B2 (ja) 2018-09-13 2019-09-11 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法
JP2024110682A Pending JP2024149496A (ja) 2018-09-13 2024-07-10 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024110682A Pending JP2024149496A (ja) 2018-09-13 2024-07-10 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法

Country Status (7)

Country Link
US (2) US20210338727A1 (enExample)
EP (1) EP3850004B1 (enExample)
JP (2) JP7520818B2 (enExample)
CN (1) CN113166225A (enExample)
AU (1) AU2019337603B2 (enExample)
CA (1) CA3112195A1 (enExample)
WO (1) WO2020056045A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
CN111423517B (zh) * 2020-04-15 2023-05-12 赛德特生物制药有限公司 一种肿瘤细胞干性限制型car及其应用
AU2021286655A1 (en) 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
WO2022215843A1 (ko) * 2021-04-06 2022-10-13 (주)에스엠티바이오 암 환자에 대하여 자연살해세포를 이용한 면역 항암 치료의 치료 반응성을 예측하는 방법
EP4337228A4 (en) * 2021-05-13 2025-07-30 Nkarta Inc DOSAGE REGIMEN FOR CANCER IMMUNOTHERAPY
US20240316102A1 (en) 2021-07-01 2024-09-26 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
JP2024540347A (ja) * 2021-11-09 2024-10-31 ウーゲン，インコーポレイテッド 記憶ｎｋ細胞と抗癌性二重特異性分子とによる組み合わせ癌療法
WO2023199961A1 (ja) * 2022-04-14 2023-10-19 第一三共株式会社 膜型サイトカイン及びｔｎｆ受容体スーパーファミリー分子の細胞内ドメインをコードするポリヌクレオチド
JP2025525439A (ja) 2022-06-30 2025-08-05 インダプタ セラピューティクス インコーポレイテッド 操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
WO2024080726A1 (ko) * 2022-10-13 2024-04-18 (주) 테라베스트 자연살해세포 및 토포이소머라제 저해제를 유효성분으로 포함하는 암 예방 및 치료용 약학 조성물
CN120092090A (zh) * 2022-11-07 2025-06-03 上海先博生物科技有限公司 工程化嵌合抗原受体免疫细胞及其应用
JP2025538424A (ja) * 2022-11-16 2025-11-28 ンカルタ・インコーポレイテッド 併用療法の投与レジメン
WO2024254774A1 (zh) * 2023-06-14 2024-12-19 香港北恒生物科技有限公司 免疫细胞联合疗法
WO2025006631A1 (en) * 2023-06-27 2025-01-02 Nkarta, Inc. Dosing regimens for treatment of cancer
CN118440901B (zh) * 2024-04-26 2025-03-07 康立泰生物医药(青岛)有限公司 转基因nk细胞及其构建方法和应用
CN118406654B (zh) * 2024-04-26 2025-03-21 中国海洋大学 经修饰的nk细胞及其构建方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123276D0 (en) * 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
NZ584288A (en) * 2004-02-06 2011-10-28 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
EP2895206A4 (en) * 2012-09-17 2016-05-04 Bruce N Gray METHOD FOR TREATING CARCINOMA
EP2948544A4 (en) * 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
WO2014140884A2 (en) * 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands
CN113307880B (zh) * 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
US10167257B2 (en) * 2014-04-04 2019-01-01 Iomet Pharma Ltd. Indole derivatives for use in medicine
US10327764B2 (en) * 2014-09-26 2019-06-25 Ethicon Llc Method for creating a flexible staple line
DK3143134T3 (da) * 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
MX2017002205A (es) * 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
JP6839074B2 (ja) * 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
WO2016168493A1 (en) * 2015-04-15 2016-10-20 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Hepatic arterial infusion of car-t cells
US12241053B2 (en) * 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
BR112018008442A2 (pt) 2015-11-05 2018-11-06 Juno Therapeutics Inc receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
US10875919B2 (en) * 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
WO2018049248A1 (en) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
WO2018081648A2 (en) * 2016-10-29 2018-05-03 Genentech, Inc. Anti-mic antibidies and methods of use
EP3567049A4 (en) * 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
CA3055200A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
BR112019019917A2 (pt) * 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais

Similar Documents

Publication Publication Date Title
JP2022500419A5 (enExample)
Alnefaie et al. Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions
Hodgins et al. Killers 2.0: NK cell therapies at the forefront of cancer control
Al-Haideri et al. CAR-T cell combination therapy: the next revolution in cancer treatment
Harris et al. Immuno-oncology combinations: raising the tail of the survival curve
Dempke et al. Second-and third-generation drugs for immuno-oncology treatment—the more the better?
CN110475571B (zh) 细胞免疫疗法前细胞毒性预调理的替代
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
JP6787792B2 (ja) がんの処置のための併用治療
Huang et al. Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma
Duru et al. A window of opportunity: targeting cancer endothelium to enhance immunotherapy
Kamrani et al. New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses
US20210290641A1 (en) Ep4 inhibitors and use thereof
KR20150080507A (ko) 면역 반응의 향상
Khan et al. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
Huang et al. Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses
JP2022189827A (ja) 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与
Su et al. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Morganti et al. Combinations using checkpoint blockade to overcome resistance
Demel et al. Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021
WO2022052874A1 (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
Dolkar et al. New developments in immunotherapy for SCLC
Li et al. Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments
Kim et al. Calcipotriol, a synthetic Vitamin D analog, promotes antitumor immunity via CD4+ T-dependent CTL/NK cell activation
Swan et al. The evolving status of immunotherapies in multiple myeloma: The future role of bispecific antibodies